鼻腔鼻窦淋巴瘤30例回顾分析  

Retrospective analysis of 30 cases with nasal cavity and paranasal sinus lymphoma

作　　者：廖礼兵[1] 严小玲[1] 张建国[1] 田慎之[1] 袁旭平[1] 肖琪[1] 

机构地区：[1]广州医学院第二附属医院耳鼻咽喉科,广东广州510260

出　　处：《现代预防医学》2012年第22期6029-6030,6032,共3页Modern Preventive Medicine

摘　　要：目的探讨鼻腔鼻窦淋巴瘤不同治疗模式的近期疗效及对远期生存质量的影响。方法针对不同分期鼻腔鼻窦淋巴瘤患者分别采用手术加同步放化疗(A)、同步放化疗(B)、手术加放疗(C)的治疗模式。结果全组患者5年总生存率66.7%,无病生存率(DFS)36.7%,A组完全缓解率(complete response rate,CR)57.1%比B组44.4%或C组42.9%均差异有统计学意义。B组44.4%比C组42.9%差异无统计学意义。5年总生存率(overall survival,OS)A组71.4%、B组66.7%﹥C组57.1%,差异有统计学意义。结论同步放化疗相对单纯放疗或化疗而言,提高了远期生存。早期较局限的鼻腔鼻窦淋巴瘤先手术再同步放化疗的治疗模式可以提高无病生存率及完全缓解率。OBJECTIVE To investigate the treatment of sinonasal lymphomas of different patterns of short-term effect and long-term effect on life quality.METHODS According to the different stages of sinonasal lymphomas were treated by operation combined with concurrent chemotherapy(A),concurrent chemoradiotherapy(B),operation plus radiotherapy(C)treatment model.RESULTS Among the patients,5 year overall survival rate was 66.7%,the disease-free survival rate(DFS)was 36.7%.The complete remission rate was 57.1% in group A(complete response rate,CR),which was better than group B(44.4%)and group C(42.9%).The complete response rate in group B had no difference compared with C group.The 5 year overall survival rate(overall survival,OS)was 71.4% in group A and 66.7% in group B,which were higher than 57.1% in group C.CONCLUSION Concurrent chemoradiotherapy improves long-term survival compared with radiotherapy alone or chemotherapy.Early circumscribed sinonasal lymphomas before operation and concurrent chemoradiation therapy can improve disease-free survival rate and the rate of complete remission.

关 键 词：鼻腔鼻窦 淋巴瘤 同步放化疗 

分 类 号：R739.62[医药卫生—肿瘤]